查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1415024

非專利藥注射劑市場：按產品類型、應用、分銷管道分類 - 2024-2030 年全球預測

Generic Injectables Market by Product (Large Molecule Injectables, Small Molecule Injectables), Type (Cytokines, Insulin, Monoclonal Antibodies), Application, Distribution Channel - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計2023年非專利藥市場規模將達300億美元，預計2024年將達331.2億美元，2030年將達到606.6億美元，複合年成長率為10.57%。

全球非專利藥注射劑市場

主要市場統計
基準年[2023] 300億美元
預測年份 [2024] 331.2億美元
預測年份 [2030] 606.6億美元
複合年成長率（%） 10.57%
學名藥注射劑市場-IMG1

非專利藥注射劑是透過注射給藥的非品牌藥物，具有與品牌產品相同的活性成分、規格、劑型、給藥途徑、品質、性能特徵和預期用途。它通常在原廠產品的專利到期後出售。非專利藥注射劑透過提供具有成本效益的品牌藥物替代品，有助於節省醫療費用並為患者提供便利。對更實惠的藥物的需求不斷成長，以及由於幾種品牌注射劑的專利到期而導致學名藥進入市場，推動了學名藥注射劑市場的發展。世界各國政府的成本控制政策也支持廣泛普及具有成本效益的非專利注射劑。此外，需要注射藥物治療的慢性疾病的增加也支持了市場的成長。儘管成長前景廣闊，但市場在維持高品質標準方面面臨挑戰，如果管理不當，可能會導致召回和聲譽受損。此外，市場競爭激烈且價格下降，這可能會阻礙非專利注射劑的採用。然而，研究重點是先進的藥物輸送系統、生物相似藥開發、永續生產以及提高產品穩定性和保存期限的配方進步，為市場擴張提供了利潤豐厚的機會。

區域洞察

美國尤其是美國的非專利藥注射劑市場正在經歷顯著成長。由於學名藥到期、政府努力最大限度地降低醫療成本以及慢性病的增加，該地區對負擔得起的專利到期藥的需求正在迅速增加。除了發達的醫療保健產業外，美洲地區也受惠於競爭激烈的市場形勢，許多參與企業不斷致力於推出新產品和具成本效益的製造流程。歐洲、中東和非洲（Europe, Middle East, and Africa）地區的非專利注射藥物市場正在穩步成長。這一業績是由旨在促進學名藥使用和對生物相似藥的重視的政府支持性衛生政策所推動的。雖然歐洲市場尤其受益於確保高品質產品的嚴格監管標準，但成本效益仍然是非專利注射劑普及的驅動力。隨著醫療基礎設施的改善和藥物取得的增加，中東和非洲的市場正在穩步發展。目前非專利學名藥領域在亞太地區正在迅速擴張。印度和中國因其龐大的人口基數、不斷上漲的醫療成本以及政府對學名藥生產的支持政策而成為這一成長的主要貢獻者。該地區還擁有大量學名藥生產商，支持了當地市場的成長。此外，慢性病盛行率的不斷上升以及新興國家加強醫療保健系統的共同努力，為亞太地區非專利藥注射劑市場的成長奠定了堅實的基礎。

FPNV定位矩陣

FPNV 定位矩陣對於評估非專利注射劑市場至關重要。我們檢視與業務策略和產品滿意度相關的關鍵指標，以對供應商進行全面評估。這種深入的分析使用戶能夠根據自己的要求做出明智的決策。根據評估，供應商被分為四個成功程度不同的像限。最前線 (F)、探路者 (P)、利基 (N) 和重要 (V)。

市場佔有率分析

市場佔有率分析是一種綜合工具，可以對非專利注射劑市場供應商的現狀進行深入而深入的研究。全面比較和分析供應商在整體收益、基本客群和其他關鍵指標方面的貢獻，以便更好地了解公司的績效及其在爭奪市場佔有率時面臨的挑戰。此外，該分析還提供了對該行業競爭特徵的寶貴考察，包括在研究基準年觀察到的累積、分散主導地位和合併特徵等因素。這種詳細程度的提高使供應商能夠做出更明智的決策並制定有效的策略，從而在市場上獲得競爭優勢。

本報告在以下方面提供了寶貴的見解：

1-市場滲透率：提供有關主要企業所服務的市場的全面資訊。

2-市場開拓：我們深入研究利潤豐厚的新興市場，並分析它們在成熟細分市場中的滲透率。

3- 市場多元化：提供有關新產品發布、開拓地區、最新發展和投資的詳細資訊。

4-競爭力評估與資訊：對主要企業的市場佔有率、策略、產品、認證、監管狀況、專利狀況、製造能力等進行全面評估。

5- 產品開發與創新：提供對未來技術、研發活動和突破性產品開發的見解。

本報告解決了以下關鍵問題：

1-非專利注射劑市場的市場規模和預測是多少？

2-在非專利藥市場預測期內需要考慮投資的產品、細分市場、應用和領域有哪些？

3-非專利藥注射劑市場的技術趨勢和法律規範是什麼？

4-非專利藥市場主要供應商的市場佔有率是多少？

5-進入非專利注射藥市場的合適型態和策略手段是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 慢性病的流行和對具成本效益藥物的需求
      • 重視延長專利有效期限及採用學名藥
      • 政府對學名藥和注射劑的有利核准
    • 抑制因素
      • 病人和醫生對品牌藥物的偏好
    • 機會
      • 有關非專利注射劑的持續研發活動
      • 建立非專利注射劑生產的長期策略夥伴關係
    • 任務
      • 對注射品質和製造差異的擔憂
  • 市場區隔分析
    • 產品：易於取得和熟悉將增加各個治療領域小分子注射劑的消費
    • 類型：在持續研究和開發具有成本效益的新治療方法中對非專利細胞激素和單株抗體的需求
    • 應用：非專利注射劑在心臟病學和腫瘤學領域的顯著優勢需要長期且永續的藥物成本
    • 通路：越來越青睞提供便利且價格具競爭力的網路商店
  • 市場趨勢分析
  • 高通膨的累積效應
  • 波特五力分析
  • 價值鍊和關鍵路徑分析
  • 法律規範

第6章非專利注射劑市場：依產品

  • 介紹
  • 聚合物注射
  • 低分子注射液

第7章非專利注射劑市場：按類型

  • 介紹
  • 細胞激素
  • 胰島素
  • 單株抗體
  • 疫苗

第8章非專利注射劑市場：依應用分類

  • 介紹
  • 心臟病學
  • 糖尿病
  • 免疫學
  • 腫瘤學

第9章非專利注射劑市場：依通路

  • 介紹
  • 醫院藥房
  • 網路處方箋店
  • 零售藥房

第10章美洲非專利注射劑市場

  • 介紹
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章亞太地區非專利注射劑市場

  • 介紹
  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第12章 歐洲、中東和非洲非專利注射劑市場

  • 介紹
  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭形勢

  • FPNV定位矩陣
  • 市場佔有率分析：主要企業
  • 主要企業競爭情境分析
    • 新產品發布和功能增強
    • 獎項/獎勵/擴展

第14章競爭產品組合

  • 主要公司簡介
    • Amgen Inc.
    • AstraZeneca PLC
    • Aurobindo Pharma Limited
    • Baxter International Inc.
    • Biocon Limited
    • Biological E. Limited
    • Bristol-Myers Squibb Company
    • Cipla Limited
    • Dr. Reddy's Laboratories Ltd.
    • Endo International PLC
    • Eugia US LLC
    • Fresenius Kabi AG
    • Gland Pharma Limited by Shanghai Fosun Pharmaceutical Co., Ltd.
    • GlaxoSmithKline PLC
    • Hikma Pharmaceuticals PLC
    • Johnson & Johnson Services, Inc.
    • Lupin Limited
    • Meitheal Pharmaceuticals, Inc.
    • Merck & Co. Inc.
    • Novartis AG
    • Novo Nordisk A/S
    • Pfizer Inc.
    • Samsung Biologics Co., Ltd.
    • Sanofi SA
    • Somerset Pharma, LLC
    • Sun Pharmaceutical Industries Ltd.
    • Teva Pharmaceutical Industries Ltd.
    • Viatris Inc.
  • 主要產品系列

第15章附錄

  • 討論指南
  • 關於許可證和定價
Product Code: MRR-C002B1C9980C

[187 Pages Report] The Generic Injectables Market size was estimated at USD 30.00 billion in 2023 and expected to reach USD 33.12 billion in 2024, at a CAGR 10.57% to reach USD 60.66 billion by 2030.

Global Generic Injectables Market

KEY MARKET STATISTICS
Base Year [2023] USD 30.00 billion
Estimated Year [2024] USD 33.12 billion
Forecast Year [2030] USD 60.66 billion
CAGR (%) 10.57%
Generic Injectables Market - IMG1

Generic injectables are non-branded pharmaceuticals that are administered by injection and have the same active ingredients, strength, dosage form, route of administration, quality, performance characteristics, and intended use as their branded counterparts. They are typically marketed after the original branded product's patent protection has expired. Generic injectables offer a cost-effective alternative to brand-name drugs, thereby contributing to healthcare savings and increased accessibility for patients. The generic injectables market is fueled by the increasing demand for more affordable pharmaceuticals and the expiration of patents for multiple branded injectables, which allows generic versions to enter the market. Cost-containment policies by governments worldwide also drive the uptake of cost-effective generic injectables. In addition, the rise in the prevalence of chronic diseases that require injectable drugs for treatment supports the market growth. Despite the promising growth, the market faces challenges due to maintaining high-quality standards, which, if not adequately managed, can lead to recalls and reputational damage. Furthermore, the market is subject to intense competition and price erosion, which can hinder the adoption of generic injectables. However, research focusing on advanced drug delivery systems, biosimilar development, sustainable production, and formulation advancements to improve product stability and storage presents lucrative opportunities for market expansion.

Regional Insights

The market for generic injectables in the Americas, and particularly in the United States, has seen significant growth. The expiration of patents for branded drugs, government initiatives to minimize healthcare costs, and the rising prevalence of chronic diseases have resulted in a surging need for affordable generic alternatives in this region. The Americas region benefits from a well-developed healthcare sector and a competitive market landscape where numerous players are constantly engaged in the introduction of new products and cost-effective manufacturing processes. The Europe, Middle East, and Africa (EMEA) region has experienced steady growth in the generic injectables market. This performance is facilitated by supportive governmental health policies aimed at promoting the use of generics, as well as an emphasis on biosimilars. The European market, in particular, benefits from stringent regulatory standards that ensure high-quality products, while cost-effectiveness remains a driving factor behind the widespread adoption of generic injectables. In the Middle East and Africa, the market is steadily evolving with the improving healthcare infrastructure and increased accessibility to medication. The Asia-Pacific (APAC) region is currently witnessing rapid expansion in the generic injectables sector. India and China, with their vast population base, increasing healthcare expenditure, and supportive government policies for generic medicine production, are contributing significantly to this growth. The region also hosts a significant number of generic drug manufacturers, which bolster the local market growth. Additionally, the growing incidence of chronic conditions, coupled with a concerted effort to enhance healthcare systems in emerging economies, provides a robust platform for the growth of the generic injectables market in APAC.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Generic Injectables Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Generic Injectables Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Generic Injectables Market, highlighting leading vendors and their innovative profiles. These include Amgen Inc., AstraZeneca PLC, Aurobindo Pharma Limited, Baxter International Inc., Biocon Limited, Biological E. Limited, Bristol-Myers Squibb Company, Cipla Limited, Dr. Reddy's Laboratories Ltd., Endo International PLC, Eugia US LLC, Fresenius Kabi AG, Gland Pharma Limited by Shanghai Fosun Pharmaceutical Co., Ltd., GlaxoSmithKline PLC, Hikma Pharmaceuticals PLC, Johnson & Johnson Services, Inc., Lupin Limited, Meitheal Pharmaceuticals, Inc., Merck & Co. Inc., Novartis AG, Novo Nordisk A/S, Pfizer Inc., Samsung Biologics Co., Ltd., Sanofi S.A., Somerset Pharma, LLC, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., and Viatris Inc..

Market Segmentation & Coverage

This research report categorizes the Generic Injectables Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Product
    • Large Molecule Injectables
    • Small Molecule Injectables
  • Type
    • Cytokines
    • Insulin
    • Monoclonal Antibodies
    • Vaccines
  • Application
    • Cardiology
    • Diabetes
    • Immunology
    • Oncology
  • Distribution Channel
    • Hospital Pharmacy
    • Online Prescription Stores
    • Retail Pharmacy
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Generic Injectables Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Generic Injectables Market?

3. What are the technology trends and regulatory frameworks in the Generic Injectables Market?

4. What is the market share of the leading vendors in the Generic Injectables Market?

5. Which modes and strategic moves are suitable for entering the Generic Injectables Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Generic Injectables Market, by Region

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Prevalence of chronic diseases and need for cost-effective medications
      • 5.1.1.2. Increasing patent expirations and emphasis on adopting generic drugs
      • 5.1.1.3. Favorable government approvals for generic drugs & injectables
    • 5.1.2. Restraints
      • 5.1.2.1. Preference for branded drugs by patients and physicians
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing R&D activities associated with generic injectable drugs
      • 5.1.3.2. Strategic long-term partnerships to manufacture generic injectables
    • 5.1.4. Challenges
      • 5.1.4.1. Concerns associated with injectable quality and manufacturing variability
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Product: Growing consumption of small molecule injectables in various therapeutic areas owing to their accessibility and familiarity
    • 5.2.2. Type: Demand for generic cytokines and monoclonal antibodies in ongoing R&D for cost-effective novel therapies
    • 5.2.3. Application: Significant benefits of generic injectables in cardiology and oncology, requiring long-term and sustainable medication costs
    • 5.2.4. Distribution Channel: Inclining preferences for online stores offering convenience and competitive pricing
  • 5.3. Market Trend Analysis
  • 5.4. Cumulative Impact of High Inflation
  • 5.5. Porter's Five Forces Analysis
    • 5.5.1. Threat of New Entrants
    • 5.5.2. Threat of Substitutes
    • 5.5.3. Bargaining Power of Customers
    • 5.5.4. Bargaining Power of Suppliers
    • 5.5.5. Industry Rivalry
  • 5.6. Value Chain & Critical Path Analysis
  • 5.7. Regulatory Framework

6. Generic Injectables Market, by Product

  • 6.1. Introduction
  • 6.2. Large Molecule Injectables
  • 6.3. Small Molecule Injectables

7. Generic Injectables Market, by Type

  • 7.1. Introduction
  • 7.2. Cytokines
  • 7.3. Insulin
  • 7.4. Monoclonal Antibodies
  • 7.5. Vaccines

8. Generic Injectables Market, by Application

  • 8.1. Introduction
  • 8.2. Cardiology
  • 8.3. Diabetes
  • 8.4. Immunology
  • 8.5. Oncology

9. Generic Injectables Market, by Distribution Channel

  • 9.1. Introduction
  • 9.2. Hospital Pharmacy
  • 9.3. Online Prescription Stores
  • 9.4. Retail Pharmacy

10. Americas Generic Injectables Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Generic Injectables Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Generic Injectables Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. FPNV Positioning Matrix
  • 13.2. Market Share Analysis, By Key Player
  • 13.3. Competitive Scenario Analysis, By Key Player
    • 13.3.1. New Product Launch & Enhancement
      • 13.3.1.1. Endo Launches First Generic Version of Noxafil (posaconazole) Injection
    • 13.3.2. Award, Recognition, & Expansion
      • 13.3.2.1. Gland Pharma gets USFDA nod for generic injectable
      • 13.3.2.2. Meitheal Pharmaceuticals Announces Expansion of Portfolio of Generic Injectable Products

14. Competitive Portfolio

  • 14.1. Key Company Profiles
    • 14.1.1. Amgen Inc.
    • 14.1.2. AstraZeneca PLC
    • 14.1.3. Aurobindo Pharma Limited
    • 14.1.4. Baxter International Inc.
    • 14.1.5. Biocon Limited
    • 14.1.6. Biological E. Limited
    • 14.1.7. Bristol-Myers Squibb Company
    • 14.1.8. Cipla Limited
    • 14.1.9. Dr. Reddy's Laboratories Ltd.
    • 14.1.10. Endo International PLC
    • 14.1.11. Eugia US LLC
    • 14.1.12. Fresenius Kabi AG
    • 14.1.13. Gland Pharma Limited by Shanghai Fosun Pharmaceutical Co., Ltd.
    • 14.1.14. GlaxoSmithKline PLC
    • 14.1.15. Hikma Pharmaceuticals PLC
    • 14.1.16. Johnson & Johnson Services, Inc.
    • 14.1.17. Lupin Limited
    • 14.1.18. Meitheal Pharmaceuticals, Inc.
    • 14.1.19. Merck & Co. Inc.
    • 14.1.20. Novartis AG
    • 14.1.21. Novo Nordisk A/S
    • 14.1.22. Pfizer Inc.
    • 14.1.23. Samsung Biologics Co., Ltd.
    • 14.1.24. Sanofi S.A.
    • 14.1.25. Somerset Pharma, LLC
    • 14.1.26. Sun Pharmaceutical Industries Ltd.
    • 14.1.27. Teva Pharmaceutical Industries Ltd.
    • 14.1.28. Viatris Inc.
  • 14.2. Key Product Portfolio

15. Appendix

  • 15.1. Discussion Guide
  • 15.2. License & Pricing

LIST OF FIGURES

  • FIGURE 1. GENERIC INJECTABLES MARKET RESEARCH PROCESS
  • FIGURE 2. GENERIC INJECTABLES MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GENERIC INJECTABLES MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GENERIC INJECTABLES MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GENERIC INJECTABLES MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GENERIC INJECTABLES MARKET DYNAMICS
  • FIGURE 7. GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 8. GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 10. GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 12. GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 14. GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. AMERICAS GENERIC INJECTABLES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 16. AMERICAS GENERIC INJECTABLES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. UNITED STATES GENERIC INJECTABLES MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 18. UNITED STATES GENERIC INJECTABLES MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. ASIA-PACIFIC GENERIC INJECTABLES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. ASIA-PACIFIC GENERIC INJECTABLES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA GENERIC INJECTABLES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA GENERIC INJECTABLES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 23. GENERIC INJECTABLES MARKET, FPNV POSITIONING MATRIX, 2023
  • FIGURE 24. GENERIC INJECTABLES MARKET SHARE, BY KEY PLAYER, 2023

LIST OF TABLES

  • TABLE 1. GENERIC INJECTABLES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GENERIC INJECTABLES MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 6. GENERIC INJECTABLES MARKET SIZE, BY LARGE MOLECULE INJECTABLES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 7. GENERIC INJECTABLES MARKET SIZE, BY SMALL MOLECULE INJECTABLES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 8. GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 9. GENERIC INJECTABLES MARKET SIZE, BY CYTOKINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GENERIC INJECTABLES MARKET SIZE, BY INSULIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GENERIC INJECTABLES MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GENERIC INJECTABLES MARKET SIZE, BY VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 14. GENERIC INJECTABLES MARKET SIZE, BY CARDIOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GENERIC INJECTABLES MARKET SIZE, BY DIABETES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GENERIC INJECTABLES MARKET SIZE, BY IMMUNOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GENERIC INJECTABLES MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 19. GENERIC INJECTABLES MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GENERIC INJECTABLES MARKET SIZE, BY ONLINE PRESCRIPTION STORES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GENERIC INJECTABLES MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS GENERIC INJECTABLES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 31. BRAZIL GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. BRAZIL GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 34. BRAZIL GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 35. CANADA GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 36. CANADA GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. CANADA GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 38. CANADA GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 39. MEXICO GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 40. MEXICO GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. MEXICO GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 42. MEXICO GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 43. UNITED STATES GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 44. UNITED STATES GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. UNITED STATES GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 47. UNITED STATES GENERIC INJECTABLES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 48. ASIA-PACIFIC GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 49. ASIA-PACIFIC GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC GENERIC INJECTABLES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 53. AUSTRALIA GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 54. AUSTRALIA GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. AUSTRALIA GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 56. AUSTRALIA GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 57. CHINA GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 58. CHINA GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. CHINA GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 60. CHINA GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 61. INDIA GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 62. INDIA GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. INDIA GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 64. INDIA GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 65. INDONESIA GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 66. INDONESIA GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. INDONESIA GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 68. INDONESIA GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 69. JAPAN GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 70. JAPAN GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. JAPAN GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 72. JAPAN GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 73. MALAYSIA GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 74. MALAYSIA GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. MALAYSIA GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 76. MALAYSIA GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 77. PHILIPPINES GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 78. PHILIPPINES GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. PHILIPPINES GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 80. PHILIPPINES GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 81. SINGAPORE GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 82. SINGAPORE GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. SINGAPORE GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 84. SINGAPORE GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 85. SOUTH KOREA GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 86. SOUTH KOREA GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH KOREA GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH KOREA GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 89. TAIWAN GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 90. TAIWAN GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. TAIWAN GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 92. TAIWAN GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 93. THAILAND GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 94. THAILAND GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. THAILAND GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 96. THAILAND GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 97. VIETNAM GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 98. VIETNAM GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. VIETNAM GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 100. VIETNAM GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA GENERIC INJECTABLES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 106. DENMARK GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 107. DENMARK GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. DENMARK GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 109. DENMARK GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 110. EGYPT GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 111. EGYPT GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. EGYPT GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 113. EGYPT GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 114. FINLAND GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 115. FINLAND GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. FINLAND GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 117. FINLAND GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 118. FRANCE GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 119. FRANCE GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. FRANCE GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 121. FRANCE GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 122. GERMANY GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 123. GERMANY GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. GERMANY GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 125. GERMANY GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 126. ISRAEL GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 127. ISRAEL GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. ISRAEL GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 129. ISRAEL GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 130. ITALY GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 131. ITALY GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. ITALY GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 133. ITALY GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 134. NETHERLANDS GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 135. NETHERLANDS GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. NETHERLANDS GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 137. NETHERLANDS GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 138. NIGERIA GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 139. NIGERIA GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. NIGERIA GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 141. NIGERIA GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 142. NORWAY GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 143. NORWAY GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 144. NORWAY GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 145. NORWAY GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 146. POLAND GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 147. POLAND GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 148. POLAND GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 149. POLAND GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 150. QATAR GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 151. QATAR GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 152. QATAR GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 153. QATAR GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 154. RUSSIA GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 155. RUSSIA GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 156. RUSSIA GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 157. RUSSIA GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 158. SAUDI ARABIA GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 159. SAUDI ARABIA GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 160. SAUDI ARABIA GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 161. SAUDI ARABIA GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 162. SOUTH AFRICA GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 163. SOUTH AFRICA GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 164. SOUTH AFRICA GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH AFRICA GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 166. SPAIN GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 167. SPAIN GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 168. SPAIN GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 169. SPAIN GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 170. SWEDEN GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 171. SWEDEN GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 172. SWEDEN GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 173. SWEDEN GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 174. SWITZERLAND GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 175. SWITZERLAND GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 176. SWITZERLAND GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 177. SWITZERLAND GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 178. TURKEY GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 179. TURKEY GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 180. TURKEY GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 181. TURKEY GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 182. UNITED ARAB EMIRATES GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 183. UNITED ARAB EMIRATES GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED ARAB EMIRATES GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED ARAB EMIRATES GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED KINGDOM GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED KINGDOM GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED KINGDOM GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED KINGDOM GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 190. GENERIC INJECTABLES MARKET, FPNV POSITIONING MATRIX, 2023
  • TABLE 191. GENERIC INJECTABLES MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 192. GENERIC INJECTABLES MARKET LICENSE & PRICING